Nektar Therapeutics (NASDAQ: NKTR) has experienced a decline in its stock price by -2.84 compared to its previous closing price of 1.41. However, the company has seen a gain of 1.48% in its stock price over the last five trading days. prnewswire.com reported 2024-06-12 that – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism – – IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 – SAN FRANCISCO, June 12, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress. NKTR-0165 is a novel, first-in-class tumor necrosis factor receptor 2 (TNFR2) agonist and bivalent antibody designed to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling.
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
The 36-month beta value for NKTR is at 0.65. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NKTR is 178.72M, and currently, shorts hold a 5.44% of that float. The average trading volume for NKTR on July 26, 2024 was 1.96M shares.
NKTR’s Market Performance
NKTR stock saw an increase of 1.48% in the past week, with a monthly gain of 28.04% and a quarterly increase of -0.72%. The volatility ratio for the week is 7.80%, and the volatility levels for the last 30 days are 10.14% for Nektar Therapeutics (NKTR). The simple moving average for the past 20 days is 3.65% for NKTR’s stock, with a 49.18% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Rodman & Renshaw repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to Rodman & Renshaw is $2 based on the research report published on June 28, 2024 of the current year 2024.
NKTR Trading at -0.88% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.94% of loss for the given period.
Volatility was left at 10.14%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares surge +26.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.71% lower at present.
During the last 5 trading sessions, NKTR rose by +1.48%, which changed the moving average for the period of 200-days by +153.23% in comparison to the 20-day moving average, which settled at $1.3360. In addition, Nektar Therapeutics saw 142.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from CHESS ROBERT, who sale 19,500 shares at the price of $1.20 back on Jun 14 ’24. After this action, CHESS ROBERT now owns 255,273 shares of Nektar Therapeutics, valued at $23,400 using the latest closing price.
ROBIN HOWARD W, the President & CEO of Nektar Therapeutics, sale 16,650 shares at $1.75 during a trade that took place back on May 17 ’24, which means that ROBIN HOWARD W is holding 863,239 shares at $29,138 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.78 for the present operating margin
- 0.61 for the gross margin
The net margin for Nektar Therapeutics stands at -1.95. The total capital return value is set at -0.47. Equity return is now at value -95.68, with -36.72 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.37. The debt to equity ratio resting at 1.08. The interest coverage ratio of the stock is -6.56.
Currently, EBITDA for the company is -129.61 million with net debt to EBITDA at -1.66. When we switch over and look at the enterprise to sales, we see a ratio of 4.98. The receivables turnover for the company is 16.6for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.10.
Conclusion
In conclusion, Nektar Therapeutics (NKTR) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
